Novartis Ag

Tom Thuren

Andrew Zalewski

Michael Shetzline

Michael H Serrano-Wu

Mark C Fishman

Shi Yin Foo

Craig Basson

Charles Meyers

The present invention relates to an IL-1&#x3b2; binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.

Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV event

The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1&#x3b2; binding antibody or functional fragment thereof.

Use of IL-1 &#x3b2; binding antibodies for treating peripheral arterial disease

The present invention relates to the use of a DGAT1 inhibitor, or a pharmaceutically acceptable salt or ester thereof, for the prevention, delay of progression or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia. The present invention further relates to the use of a pharmaceutical composition comprising a DGAT1 inhibitor, or a pharmaceutically acceptable salt or ester thereof, for the prevention, delay of progression or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia.

Uses of DGAT1 inhibitors

Growing community of inventors

Succasunna, NJ, United States of America

Tom Thuren